Lipoprotein-bound active agents traverse epithelial layers using fatty acid surfactant carriers, resolving low permeability constraints.
A CRISPR-Cas9 vector delivers multiple guide RNAs to introduce specific genetic mutations in transgenic animal models.
An AAV8 vector delivers IGF-1 to pancreatic beta cells, protecting against autoimmune destruction while maintaining physiological glucose regulation.
Nucleic acid assemblies enclose CRISPR components to enable targeted delivery while reducing cytotoxicity and off-target editing.
Phosphorothioate anti-miR-141-3p oligonucleotides encapsulated in biocompatible nanoparticles modulate target levels to reduce infarct volume.
A cell resealing system incorporates arbitrary molecules into exosomes using biological toxins, ATP, and calcium ions.
A c-Met targeted aptamer drug conjugate links SL1 to a tubulin inhibitor via covalent bonds.